- Trials with a EudraCT protocol (17)
 - Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
 
		
	   		
	   		    
                    
                   	
                   	    17 result(s) found for: Congenital analgesia.
                    
                
			
   			
		
		Displaying page 1 of 1.
	
	
| EudraCT Number: 2007-000736-10 | Sponsor Protocol Number: | Start Date*: 2007-11-05 | |||||||||||
| Sponsor Name: | |||||||||||||
| Full Title: A comparison of pethidine/meperidine intramusculary and remifentanil patient-controlled analgesia during labor in Westfriesgasthuis | |||||||||||||
| Medical condition: Women in labour | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: NL (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-002209-12 | Sponsor Protocol Number: ABR59689 | Start Date*: 2017-06-21 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Erasmus MC-Sophia Children's Hospital | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: Less opioids after major abdominal surgery in young infants using wound catheter infusion with local anesthetics: a randomized controlled trial. | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Children < 1 year of age undergoing major open abdominal surgery. | |||||||||||||||||||||||||||||||||||||||||||
					
						
							
  | 
			|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: NL (Prematurely Ended) | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2015-005538-23 | Sponsor Protocol Number: RB15.213 | Start Date*: 2016-02-03 | |||||||||||
| Sponsor Name:CHRU de Brest | |||||||||||||
| Full Title: Analgesia and physiotherapy in children with cerebral palsy (ANTALKINECP): Double blind cross-over placebo controlled study of Ibuprofen in children with cerebral palsy undergoing physiotherapy | |||||||||||||
| Medical condition: Cerebral Palsy | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-005161-20 | Sponsor Protocol Number: SCC01 | Start Date*: 2012-02-14 | |||||||||||
| Sponsor Name:University College Dublin Clinical Research Centre | |||||||||||||
| Full Title: A Randomised Controlled Double-Blind Trial of Intranasal Fentanyl versus Intravenous Morphine in the Emergency Department Treatment of Severe Painful Sickle Cell Crises in Children | |||||||||||||
| Medical condition: Severe Painful Sickle Cell Disease Crises in Children | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: IE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-001056-35 | Sponsor Protocol Number: TXA | Start Date*: 2014-11-24 | |||||||||||
| Sponsor Name:IRCCS Istituto Giannina Gaslini | |||||||||||||
| Full Title: The Effectiveness and Population Pharmacokinetics and Pharmacogenomics of a Reduced Dose of Tranexamic Acid for Craniosynostosis Surgery: A multicenter study. The TXA Study. | |||||||||||||
| Medical condition: craniosynostosis | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-005091-26 | Sponsor Protocol Number: SANNI-project:02 | Start Date*: 2018-02-13 | 
| Sponsor Name:Skåne University Hospital | ||
| Full Title: Clonidine for analgesia to preterm infants during neonatal intensive care – a prospective pharmacokinetic/pharmacodynamic/pharmacogenetic observational study. Cohort 2 in The SANNI project. | ||
| Medical condition: Sick preterm infants undergoing neonatal intensive care. | ||
| Disease: | ||
| Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
| Trial protocol: SE (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-002470-20 | Sponsor Protocol Number: SANNI-project:01 | Start Date*: 2017-04-11 | 
| Sponsor Name:Skåne University Hospital | ||
| Full Title: Fentanyl and Clonidine for analgesia during hypothermia in term asphyxiated infants – a prospective pharmacokinetic/ pharmacodynamic/ pharmacogenetic observational study. Cohort 1 in The SANNI proj... | ||
| Medical condition: Infants with induced hypothermic treatment after perinatal asphyxia | ||
| Disease: | ||
| Population Age: Newborns, Under 18 | Gender: Male, Female | |
| Trial protocol: SE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2017-002803-81 | Sponsor Protocol Number: TREX | Start Date*: 2020-04-03 | |||||||||||
| Sponsor Name:IRCCS ISTITUTO GIANNINA GASLINI | |||||||||||||
| Full Title: Neurodevelopmental outcome after standard dose sevoflurane versus low-dose sevoflurane/dexmedetomidine/remifentanil anaesthesia in young children | |||||||||||||
| Medical condition: Children under the age of 2 years having surgery lasting at least 2 hours | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-004471-39 | Sponsor Protocol Number: IMR-SCD-301 | Start Date*: 2020-06-24 | |||||||||||
| Sponsor Name:IMARA, Inc. | |||||||||||||
| Full Title: A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease | |||||||||||||
| Medical condition: Sickle Cell Disease | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) NL (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-002101-19 | Sponsor Protocol Number: CACZ885X2206 | Start Date*: 2016-11-22 | |||||||||||
| Sponsor Name:Novartis Pharma Services AG | |||||||||||||
| Full Title: A multiple-dose, subject- and investigator-blinded, placebo-controlled, parallel design study to assess the efficacy, safety and tolerability of ACZ885 (canakinumab) in pediatric and young adult pa... | |||||||||||||
| Medical condition: Sickle cell anemia | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-002945-41 | Sponsor Protocol Number: 78464317 | Start Date*: 2020-09-24 | ||||||||||||||||||||||||||
| Sponsor Name:Lone Nikolajsen | ||||||||||||||||||||||||||||
| Full Title: The use of intraoperative methadone in children undergoing open urological surgery | ||||||||||||||||||||||||||||
| Medical condition: Postoperative pain in children undergoing open urological surgery | ||||||||||||||||||||||||||||
					
						
							
  | 
			||||||||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Under 18 | Gender: Male | |||||||||||||||||||||||||||
| Trial protocol: DK (Prematurely Ended) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2013-002986-21 | Sponsor Protocol Number: MST-188-01 | Start Date*: 2014-06-16 | |||||||||||
| Sponsor Name:Mast Therapeutics, Inc. | |||||||||||||
| Full Title: Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Clinical Trial of MST-188 (purified ... | |||||||||||||
| Medical condition: Sickle Cell Disease with Vaso-Occlusive Crisis | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) ES (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-004697-25 | Sponsor Protocol Number: V528Nov22 | Start Date*: 2020-09-14 | |||||||||||
| Sponsor Name:The Rotunda Hospital | |||||||||||||
| Full Title: The Home Induction trial: A randomised open-label trial to assess outpatient induction of labour, and compare efficacy of Propess vs Dilapan-S® for induction of labour at 39 weeks’ gestation in nor... | |||||||||||||
| Medical condition: Normal risk nulliparous women who have no pregnancy-related or medical contraindication to Induction of Labour | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: IE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-000187-15 | Sponsor Protocol Number: MK-8616-145 | Start Date*: 2017-09-18 | |||||||||||
| Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
| Full Title: A Phase 4 Randomized, Active-Comparator Controlled Clinical Trial to Study the Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or Vecu... | |||||||||||||
| Medical condition: Reversal of neuromuscular blockade | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Completed) DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-001746-10 | Sponsor Protocol Number: CSEG101A2301 | Start Date*: 2019-07-08 | ||||||||||||||||
| Sponsor Name:Novartis Pharma AG | ||||||||||||||||||
| Full Title: A phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus placebo, with or without Hydroxyurea/ Hydroxycarbamide Therapy, in Adole... | ||||||||||||||||||
| Medical condition: Sickle Cell Disease with vaso-occlusive crisis | ||||||||||||||||||
					
						
							
  | 
			||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) BE (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) GR (Completed) DE (Completed) FI (Trial now transitioned) ES (Ongoing) IT (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2017-001747-12 | Sponsor Protocol Number: CSEG101B2201 | Start Date*: 2019-05-24 | ||||||||||||||||
| Sponsor Name:Novartis Pharma AG | ||||||||||||||||||
| Full Title: A phase 2, Multicenter, Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab, with or without Hydroxyurea/Hydroxycarbamide, in Sequential, Descending Age Groups o... | ||||||||||||||||||
| Medical condition: Sickle Cell Disease with Vaso-Occlusive Crisis | ||||||||||||||||||
					
						
							
  | 
			||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Restarted) FR (Completed) BE (Completed) IT (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2017-000188-33 | Sponsor Protocol Number: MK-8616-146 | Start Date*: 2017-10-27 | |||||||||||
| Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
| Full Title: A Phase 4 Randomized, Active-Comparator Controlled Trial to Study the Efficacy and Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or ... | |||||||||||||
| Medical condition: Reversal of neuromuscular blockade | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) BE (Completed) AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
			Subscribe to this Search
To subscribe to the RSS feed for this search click here
			.
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
		
			
To subscribe to the RSS feed for this search click here
			.
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
		| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
    	Query did not match any studies.